ECSP045190A - Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra - Google Patents

Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra

Info

Publication number
ECSP045190A
ECSP045190A EC2004005190A ECSP045190A ECSP045190A EC SP045190 A ECSP045190 A EC SP045190A EC 2004005190 A EC2004005190 A EC 2004005190A EC SP045190 A ECSP045190 A EC SP045190A EC SP045190 A ECSP045190 A EC SP045190A
Authority
EC
Ecuador
Prior art keywords
disease
diabetic
renal
pharmaceutically acceptable
vascular
Prior art date
Application number
EC2004005190A
Other languages
English (en)
Inventor
Randy Lee Webb
Gary Michael Ksander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045190A publication Critical patent/ECSP045190A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende una combinación de (i) el antagonista AT 1 valsartan o una sal farmacéuticamente aceptable del mismo y (ii) un inhibidor NEP (endopeptidasa neutra) o una sal farmacéuticamente aceptable del mismo y opcionalmente un portador farmacéuticamente aceptable y a un método para el tratamiento o prevención de una condición o enfermedad seleccionada del grupo que consiste de hipertensión, falla cardiaca tal como falla cardiaca congestiva (aguda o crónica), disfunción ventricular izquierda y cardiomiopatía hipertrófica, miopatía cardiaca diabética, arritmias superventricular y ventricular, fibrilación auricular, agitación auricular, remodelación vascular dañina, infarto al miocardio y sus secuelas, ateroesclerosis, angina (ya sea estable o inestable), insuficiencia renal (diabética y no diabética), falla cardiaca, angina de pecho, diabetes, aldosteronismo secundario, hipertensión pulmonar primaria y secundaria, condiciones de falla renal, tales como nefropatía diabética, glomerulonefritis, escleroderma, esclerosis glormerular, proteinuria de enfermedad renal primaria, y también hipertensión vascular renal, retinopatía diabética, la administración de otros trastornos vasculares, tales como migraña, enfermedad vascular periférica, enfermedad de Raynaud, hiperplasia luminal, disfunción cognitiva (tal como la enfermedad de Alzheimer), glaucoma y choque, que comprende administrar una cantidad terapéuticamente efectiva de la composición farmacéutica a un mamífero en la necesidad del mismo.
EC2004005190A 2002-01-17 2004-07-14 Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra ECSP045190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34966002P 2002-01-17 2002-01-17

Publications (1)

Publication Number Publication Date
ECSP045190A true ECSP045190A (es) 2004-08-27

Family

ID=23373410

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005190A ECSP045190A (es) 2002-01-17 2004-07-14 Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra

Country Status (29)

Country Link
EP (1) EP1467728B1 (es)
JP (2) JP4820056B2 (es)
KR (2) KR100984939B1 (es)
CN (2) CN1615134A (es)
AT (1) ATE370732T1 (es)
AU (1) AU2003206738C1 (es)
BE (1) BE2016C025I2 (es)
BR (2) BR122018015003B8 (es)
CA (1) CA2472399C (es)
CO (1) CO5600999A2 (es)
CY (2) CY1106959T1 (es)
DE (1) DE60315795T2 (es)
DK (1) DK1467728T3 (es)
EC (1) ECSP045190A (es)
ES (1) ES2290429T3 (es)
FR (1) FR16C0019I2 (es)
HU (1) HUS1600024I1 (es)
IL (2) IL162661A0 (es)
LU (1) LU93074I2 (es)
MX (1) MXPA04006917A (es)
NL (1) NL300811I2 (es)
NO (2) NO333191B1 (es)
NZ (1) NZ533968A (es)
PL (1) PL212318B1 (es)
PT (1) PT1467728E (es)
RU (1) RU2334513C3 (es)
SI (1) SI1467728T1 (es)
WO (1) WO2003059345A1 (es)
ZA (1) ZA200405117B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2384346C2 (ru) * 2004-06-23 2010-03-20 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
AU2005318365B2 (en) * 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
BRPI0806700A8 (pt) 2007-01-12 2019-01-22 Novartis Ag processo
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
ES2536514T3 (es) * 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
CN101774941A (zh) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
CA2763572C (en) 2009-05-28 2017-10-17 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CA2806780A1 (en) 2010-08-23 2012-03-01 Novartis Ag Process for the preparation of intermediates for the manufacture of nep inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
SI4321157T1 (sl) * 2013-08-26 2025-03-31 Novartis Ag Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (en) * 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
PL3218351T3 (pl) 2014-11-14 2019-12-31 Zentiva K.S. Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
CN107074744B (zh) * 2014-12-03 2019-06-18 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
CN110938042B (zh) * 2014-12-08 2022-12-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
CN106138069A (zh) * 2015-04-21 2016-11-23 刘春丽 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
RS64242B1 (sr) 2015-05-11 2023-06-30 Novartis Ag Režim doziranja sakubitril-valsartana za lečenje srčane insuficijencije
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397248A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种lcz696结晶粉末及其制备方法
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN105348209B (zh) * 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
WO2017097275A1 (en) 2015-12-11 2017-06-15 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
HK1256865A1 (zh) 2016-02-03 2019-10-04 Novartis Ag 有机化合物的盖伦制剂
EP4609912A3 (en) 2016-02-03 2025-11-12 Novartis AG New use of a combination of sacubitril and valsartan
EP3524250B1 (en) 2016-10-08 2025-07-16 Wuhan LL Science And Technology Development Co., Ltd. Pharmaceutical composition comprising a neutral endopeptidase (nep) inhibitor and an azilsartan ester derivative and use thereof for treating cardiovascular diseases
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh) 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
WO2021158084A1 (ko) * 2020-02-07 2021-08-12 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
EP4640213A1 (en) 2022-12-20 2025-10-29 THPharm Corp. Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker
JP2025541480A (ja) 2022-12-20 2025-12-18 ティーエイチファーム コーポレーション ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む心血管疾患の予防または治療用薬学的組成物
CN116687921A (zh) * 2023-06-14 2023-09-05 宁波大学 沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1256692A (en) * 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
JP2003533440A (ja) * 2000-04-03 2003-11-11 ブリストル−マイヤーズ スクイブ カンパニー 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
IL153428A0 (en) * 2000-06-22 2003-07-06 Novartis Ag Solid valsartan pharmaceutical compositions
IL153882A0 (en) * 2000-07-19 2003-07-31 Novartis Ag Valsartan salts
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
CN1615134A (zh) 2005-05-11
NO2016009I2 (no) 2016-05-18
CN102091330B (zh) 2015-04-08
EP1467728B1 (en) 2007-08-22
CA2472399A1 (en) 2003-07-24
KR100984939B9 (ko) 2024-07-17
NO2016009I1 (no) 2016-05-18
ATE370732T1 (de) 2007-09-15
FR16C0019I1 (es) 2016-06-24
IL162661A (en) 2010-11-30
PT1467728E (pt) 2007-11-14
RU2334513C3 (ru) 2017-10-24
FR16C0019I2 (fr) 2017-12-08
PL212318B1 (pl) 2012-09-28
AU2003206738C1 (en) 2020-01-30
LU93074I2 (fr) 2016-07-18
CY1106959T1 (el) 2012-01-25
CY2016013I2 (el) 2016-10-05
BR122018015003B1 (pt) 2018-11-21
NO20043380L (no) 2004-10-07
BR0306907A (pt) 2004-12-21
RU2334513C2 (ru) 2008-09-27
AU2003206738A1 (en) 2003-07-30
JP2011207898A (ja) 2011-10-20
DK1467728T3 (da) 2007-12-27
AU2003206738B2 (en) 2006-12-21
NO333191B1 (no) 2013-03-25
HUS1600024I1 (hu) 2016-06-28
PL369773A1 (en) 2005-05-02
IL162661A0 (en) 2005-11-20
KR20040078127A (ko) 2004-09-08
EP1467728A1 (en) 2004-10-20
JP2005514441A (ja) 2005-05-19
JP4820056B2 (ja) 2011-11-24
KR100984939B1 (ko) 2010-10-01
ES2290429T3 (es) 2008-02-16
ZA200405117B (en) 2005-08-31
NZ533968A (en) 2006-10-27
RU2004125178A (ru) 2005-06-10
MXPA04006917A (es) 2004-12-06
NL300811I2 (es) 2016-07-27
SI1467728T1 (sl) 2008-02-29
CO5600999A2 (es) 2006-01-31
CY2016013I1 (el) 2016-10-05
DE60315795T2 (de) 2008-06-05
BE2016C025I2 (es) 2022-05-17
DE60315795D1 (de) 2007-10-04
BR122018015003B8 (pt) 2021-07-27
KR20100057704A (ko) 2010-05-31
CA2472399C (en) 2012-02-21
WO2003059345A1 (en) 2003-07-24
CN102091330A (zh) 2011-06-15
BRPI0306907B1 (pt) 2018-10-30
BRPI0306907B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ECSP045190A (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
WO2007106708A3 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
AR040017A1 (es) Combinacion de compuestos organicos
ECSP045428A (es) Composicion farmaceutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diuretico
LU92992I2 (fr) Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables
WO2007045663A3 (en) Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
BR0317384A (pt) Combinações de valsartan com inibidores de cox-2